TABLE 1

Selected Clinical Studies Using Molecular Probes Other Than ¹⁸F-FDG for Monitoring of Therapy with PET

Agent	Tumor type or stage	Authors	Year	No. of patients	Criteria for response on PET	Outcome measures	Hazard ratio	P
¹⁸F-FLT	Recurrent malignant glioma	Chen et al. (57)	2007	19	SUV decrease of 25%	Overall survival and TTP	5.0	0.02
¹⁸F-FLT	Rectal cancer	Wieder et al. (55)	2007	10	% decrease in SUV^*	Histopathologic response (<10% residual tumor)	NR	NS
¹⁸F-FLT	Lymphoma	Herrmann et al. (58)	2007	14	Posttherapy SUV^*	Complete vs. partial response	NR	0.009
¹⁸F-FLT	Lymphoma	Kasper et al. (47)	2007	48	SUV < 1.5	Overall survival	NR	0.016
⁶⁰Cu-ATSM	Non–small cell lung cancer, IA–IV	Dehdashti et al. (84)	2003	14	T/M < 3.0	Response to therapy	NR	0.002
⁶⁰Cu-ATSM	Cervical cancer, Ib1–IVa	Dehdashti et al. (83)	2008	38	T/M < 3.5	Progression-free survival	NR	0.01
⁶⁰Cu-ATSM	Rectal cancer, T2–T4	Dietz et al. (85)	2008	17	T/M < 2.6	Progression-free survival	NR	0.05
¹⁸F-FMISO	Head and neck cancer	Rajendran et al. (96)	2006	73	T/B_max ratio > 1.6^†	Overall survival	1.68	0.002
¹⁸F-FMISO	Glioblastoma multiforme	Spence et al. (97)	2008	22	T/B_max ratio > 2.06^†	Overall survival	1.46	0.0002
¹⁸F-FMISO	Head and neck cancer, III–IV	Rischin et al. (99)^‡	2006	45	Qualitative scoring	Locoregional failure (with different treatment regimens)
¹¹C-MET^§	Malignant glioma, II–IV	Galldiks et al. (104)	2006	15	Decrease in % uptake	TTP	NR	0.01
¹⁸F-FES	Breast cancer	Dehdashti et al. (140)	2008	41	Pretherapy SUV ≥ 2	Overall survival	NR	NS
¹⁸F-FES	Breast cancer	Dehdashti et al. (144)	1999	11	% decrease in SUV^*	Clinical response	NR	0.008
¹⁸F-FES	Breast cancer	McGuire et al. (141)	1991	16	NR	Clinical response	NR	NR
¹⁸F-FES	Breast cancer	Mortimer et al. (143)	2001	40	Pretherapy SUV^and % decrease in SUV^	Clinical response	NR for both criteria	0.0007 for pretherapy SUV and 0.0003 for % decrease in SUV
¹⁸F-FES	Breast cancer	Mortimer et al. (145)	1996	43	Pretherapy SUV ≥ 1.0	Clinical response	NR	NS
¹⁸F-FES	Breast cancer	Linden et al. (142)	2006	47	SUV ≥ 1.5	Tumor response (modified RECIST)	NR	0.01

↵* No prospective SUV threshold was used; retrospective statistical correlations were derived.
↵† T/B ratio of ≥1.2 indicated severe hypoxia.
↵‡ See Rischin et al. (99) for hazard ratio and P value data; multiple treatment regimens were used.
↵§ See also Table 2 in article by Singhal et al. (103).
NR = not reported; NS = not statistically significant.